Research from AARP has found that around $1,100 in prescription drug costs could be saved by more than a million seniors, due to the Inflation Reduction Act (IRA).
Beginning in January 2025, a new provision will cap annual out-of-pocket spending for Medicare Part D enrollees at $2,000, a significant improvement for those who previously faced unlimited cost-sharing even after reaching catastrophic coverage.
AARP’s analysis estimates that 3.2 million Part D enrollees, or 8.4%, will benefit from this cap in 2025, with the number rising to 4.1 million, or 9.6%, by 2029.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze